Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity Disclosure (Details)

Stockholders' Equity Disclosure (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended	6 Months Ended		1 Months Ended		3 Months Ended	6 Months Ended		6 Months Ended
Stockholders' Equity Disclosure (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014 Series B Preferred Stock	Jun. 30, 2014 Series C Preferred Stock	May 31, 2014 Series D Preferred Stock	Jan. 31, 2014 Series D Preferred Stock	Jun. 30, 2014 Series D Preferred Stock	Jun. 30, 2014 Series D Preferred Stock	Oct. 31, 2013 Series D Preferred Stock	Jun. 30, 2014 2011 Equity Incentive Plan, January 13, 2014	Jun. 30, 2014 2011 Equity Incentive Plan, January 16, 2014	Jun. 30, 2014 2011 Equity Incentive Plan, February 1, 2014	Jun. 30, 2014 2011 Equity Incentive Plan, April 4, 2014	Jun. 30, 2014 2011 Equity Incentive Plan, June 19, 2014	Jun. 30, 2014 2011 Equity Incentive Plan, June 19, 2014 (2)	Jun. 30, 2014 Series D Unit offering	Jun. 30, 2014 Non-public offering of notes and warrants	Jun. 30, 2014 Non-public offering of notes and warrants(2)
Common stock authorized	20,000,000		20,000,000		20,000,000
Common shares issued	8,430,665		8,430,665		8,082,000
Common stock outstanding	8,283,730		8,283,730		8,082,000
Preferred stock authorized	4,500,000		4,500,000		4,500,000
Preferred stock outstanding	887,303		887,303		1,005,648
Preferred shares converted to common shares						101,935	45,000
Accumulated dividends released						$ 40,529
Annual dividend rate							$ 0.16				$ 0.24
Dividends accumulated							17,870
Dividends payable							17,870			49,237	49,237
Shares outstanding										887,303	887,303
Units offered (Common Stock and Warrants)												772,352
Units offered (Common Stock and Warrants), price per unit												$ 3.00
Units offered (Common Stock and Warrants), potential proceeds												2,317,056
Units offered (Common Stock and Warrants), additional over-allotment												1,000,000
Units offered (Common Stock and Warrants), potential proceeds for additional over-allotment												3,000,000
Units sold during offering								118,655	53,332
Gross proceeds from units sold in offering								355,966	159,996
Issuance costs									6,000
Dividends paid										45,665	89,683
Original issue price per share										$ 3.00	$ 3.00
Beneficial conversion feature (BCF)											24,279
Number of options granted			298,000		410,000								94,000	40,000	50,000	4,000	10,000	100,000
Stock-based compensation expense	34,313	30,371	163,721	49,693
Unrecognized compensation expense	$ 449,286		$ 449,286
Number of warrants issued																			85,993	283,329	239,997